{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:01:24Z","timestamp":1784797284396,"version":"3.55.0"},"reference-count":87,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"United States Department of Veterans Affairs Health Systems"},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Oral anticoagulants (OACs), including vitamin K antagonists and direct-acting OACs, are commonly used for the prevention and treatment of thrombosis. OAC-treated patients may require urgent anticoagulation reversal in circumstances of life-threatening bleeding or emergent surgery. Despite the availability of Food and Drug Administration-approved OAC reversal agents, published treatment guidelines, and institutional protocols, use of OAC reversal products and dosing vary considerably and off-label use is common. We review key factors influencing current clinical practice and examine barriers to the successful implementation of anticoagulation protocols, including discrepancies in the definition of major bleeding, dosing considerations, variability in laboratory testing practices, inconsistent study endpoints, formulary considerations, and the use of OAC reversal agents in special populations. We provide our expert opinion on best practices for oral anticoagulant reversal and an anticoagulation reversal protocol that could be implemented by healthcare institutions to standardize and optimize clinical practice.<\/jats:p>","DOI":"10.1177\/10760296261442058","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:15:51Z","timestamp":1776690951000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion on Implementing Oral Anticoagulation Reversal Protocols in US Hospitals"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-3468","authenticated-orcid":false,"given":"Karen","family":"Berger","sequence":"first","affiliation":[{"name":"Nova Southeastern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7181","authenticated-orcid":false,"given":"Andrew J.","family":"Webb","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6335-897X","authenticated-orcid":false,"given":"Alyssa D.","family":"Rabon","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2249-6150","authenticated-orcid":false,"given":"Laura E.","family":"Celmins","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-3477","authenticated-orcid":false,"given":"Shannon","family":"Lovett","sequence":"additional","affiliation":[{"name":"Stritch School of Medicine, Loyola University Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dixon","sequence":"additional","affiliation":[{"name":"Legacy Emanuel Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6542-518X","authenticated-orcid":false,"given":"Megan A.","family":"Rech","sequence":"additional","affiliation":[{"name":"Hines VA Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.053"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.07.101"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjane.2021.03.007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2021.02.024"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2015.09.035"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.09.001"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25475"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002057"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000407"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024893"},{"key":"e_1_3_3_13_2","unstructured":"US Food and Drug Administration. Update on the Safety of Andexxa. Accessed January 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/update-safety-andexxa."},{"key":"e_1_3_3_14_2","unstructured":"AstraZeneca AB. ONDEXXYA\u00ae (andexanet alfa) SmPC. Accessed January 27 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ondexxya-epar-product-information_en.pdf."},{"key":"e_1_3_3_15_2","unstructured":"AstraZeneca Canada. ONDEXXYA\u00ae (andexanet alfa) product monograph. Accessed January 27 2026. https:\/\/pdf.hres.ca\/dpd_pm\/00071399.PDF."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-015-0222-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2295"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231179682"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231176808"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130243"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad123"},{"key":"e_1_3_3_23_2","unstructured":"Wells GA Elliott J Kelly S Bai Z Boucher M Skidmore M et al. Dual antiplatelet therapy following percutaneous coronary intervention: Clinical and economic impact of standard versus extended duration. Accessed April 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542937\/pdf\/Bookshelf_NBK542937.pdf."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.23889\/ijpds.v8i1.2144"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0221"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000464"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313040"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028021993239"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08787.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R497"},{"key":"e_1_3_3_32_2","unstructured":"Octapharma. Balfaxar (prothrombin complex concentrate) package insert. Accessed September 26 2025. https:\/\/www.fda.gov\/media\/170477\/download."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002283"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61685-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13191"},{"key":"e_1_3_3_36_2","unstructured":"CSL Behring GmbH. KCENTRA (prothrombin complex concentrate) package insert. Accessed September 26 2025. https:\/\/labeling.cslbehring.com\/PI\/US\/Kcentra\/EN\/Kcentra-Prescribing-Information.pdf."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12539"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006212"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.11.066"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.019"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.08.054"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009015"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.05.086"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.04.049"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100107"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab326"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.1462"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17470"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74481-7"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2015.1.117.3916182"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1692-1415"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1829"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003061"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54916"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/00031348241241726"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006656"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2017.5.33092"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13217"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-010-0109-2"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12708"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.612"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2017:11:2"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.762872"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020962794"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16247"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618774498"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.110.004747"},{"key":"e_1_3_3_68_2","unstructured":"Janssen Pharmaceuticals. XARELTO\u00ae prescribing information. Accessed September 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf."},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.860369"},{"key":"e_1_3_3_70_2","unstructured":"Bristol-Myers Squibb. ELIQUIS\u00ae (apixaban) package insert. Accessed September 26 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220073s000lbl.pdf."},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14371"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29484"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000002847"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241248172"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105501"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001021"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.10.032"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000000866"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70227-X"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.2450\/2019.0245-18"},{"issue":"5","key":"e_1_3_3_81_2","first-page":"594","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"76","author":"Mayer S","year":"2008","unstructured":"Mayer S, Brun N, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;76(5):594\u2010622.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/08850666211012650"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231198038"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066620903027"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.11.037"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-020-01153-5"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab479"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2525"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261442058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261442058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261442058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:11:11Z","timestamp":1784794271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261442058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":87,"alternative-id":["10.1177\/10760296261442058"],"URL":"https:\/\/doi.org\/10.1177\/10760296261442058","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261442058"}}